ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60

RESMED INC

2026-Q3 EPS reported $7.79 revenue$4,189,796,000

Revenue $1,431.4M (+11% reported, +8% constant currency).
GAAP diluted EPS $2.74 (+10% YoY); non-GAAP diluted EPS $2.86 (+21% YoY).
GAAP gross margin 62.2% (+290 bps); non-GAAP gross margin 62.8% (+290 bps).
Quarterly dividend $0.60/share declared; record 5/14/2026, payable 6/18/2026.
Operating cash flow $554M; $262M returned via buybacks and dividends in Q3.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RESMED INC reported the quarter ended March 31, 2026 results: revenue $1,431.4, net income $398.7, EPS $2.74.

Period: the quarter ended March 31, 2026
Revenue: $1,431.4
Net income: $398.7
EPS: $2.74
Result: reported results

Exact text from the filing

Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended March 31, 2026 March 31, 2025 % Change Constant Currency (A) Revenue $ 1,431.4 $ 1,291.7 11 % 8 % Gross margin 62.2 % 59.3 % 5 Non-GAAP gross margin (B) 62.8 % 59.9 % 5 Selling, general, and administrative expenses 285.7 245.3 16 11 Non-GAAP selling,

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-26-197192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.